Juvenile neuronal ceroid lipofuscinosis (CLN3 disease)

AAV-mediated CLN3 gene replacement via intrathecal or intracerebroventricular delivery is the primary gene therapy strategy for CLN3 disease (juvenile neuronal ceroid lipofuscinosis, Batten disease). The c.1054C>T (p.Gln352Ter) nonsense variant truncates CLN3 near the C-terminus, eliminating the final transmembrane domain and cytoplasmic tail required for proper lysosomal membrane localization and function. As a complete loss-of-function allele, it is mechanistically appropriate for gene replacement.

CLN3 encodes battenin/CLN3 protein, a multipass transmembrane protein localized to lysosomes and late endosomes. Its exact biochemical function remains incompletely understood, but it participates in lysosomal homeostasis, autophagy regulation, and potentially lipid/glycosphingolipid metabolism. CLN3 disease is the most common NCL subtype, typically presenting at age 4-7 with progressive vision loss, followed by cognitive decline, seizures, and motor deterioration. Weill Cornell Medical College / Abeona Therapeutics initiated an intrathecal AAV9-CLN3 gene therapy trial. Preclinical studies in Cln3-knockout mice and the CLN3Δex7/8 knock-in model (which recapitulates the common ~1 kb deletion founder variant) showed reduced storage material accumulation and improved neuropathological markers after AAV-CLN3 delivery. The p.Gln352Ter variant produces a truncated protein missing the last ~30 residues including transmembrane domain 6 and the C-terminal cytoplasmic tail, which is critical for lysosomal targeting signals.

CLN3 disease is a diffuse neurodegenerative process affecting the entire CNS including the retina — achieving widespread transduction with intrathecal AAV is challenging, and retinal disease may require separate subretinal or intravitreal delivery. The slow progression of juvenile NCL (over decades) makes clinical trial design difficult: meaningful endpoints require years of follow-up. The function of CLN3 protein is still not fully elucidated, complicating biomarker development for target engagement. The common pathogenic variant in CLN3 disease is a ~1 kb genomic deletion (c.461-280_677+382del), not a point mutation — the c.1054C>T variant is less common, and trial populations may not include this specific genotype. No pivotal trial results have been published for CLN3 gene therapy as of the knowledge cutoff.

For CLN3 c.500T>A (p.Val167Asp), a pathogenic missense variant in the CLN3/battenin transmembrane protein that causes juvenile neuronal ceroid lipofuscinosis (JNCL/CLN3 Batten disease), intrathecal AAV-mediated CLN3 gene delivery represents the primary gene therapy strategy under investigation. Unlike soluble lysosomal enzymes (which benefit from cross-correction via secretion-recapture), CLN3 is a transmembrane protein localized to lysosomes and endosomes that cannot be secreted and taken up by neighboring cells. This fundamental biology means that each neuron must be individually transduced, making delivery and biodistribution the central challenge. Val167 is in a transmembrane domain; the V167D substitution introduces a charged residue into the lipid bilayer, likely destabilizing membrane insertion.

Weimer et al. (2021) demonstrated that intrathecal AAV9-CLN3 injection in Cln3-null mice reduced lysosomal storage material, improved neuroinflammatory markers, and partially preserved motor function. The AAV gene therapy program for CLN3 Batten disease is being developed with support from the Batten Disease Support and Research Association. For CLN2 (a related NCL caused by soluble enzyme TPP1 deficiency), cerliponase alfa (Brineura, intracerebroventricular enzyme replacement) received FDA approval in 2017, providing precedent for CNS-directed therapies in NCLs — but this ERT approach is not applicable to CLN3 due to the transmembrane nature of battenin. The natural history of JNCL includes progressive vision loss (typically age 4-7), seizures, cognitive decline, and death in the second to third decade. No disease-modifying therapy is currently approved.

The transmembrane nature of CLN3 protein precludes cross-correction between cells, meaning that therapeutic benefit is directly proportional to the fraction of neurons transduced — a much higher transduction threshold than for secreted lysosomal enzymes. Achieving near-complete CNS transduction via intrathecal AAV is currently not feasible; typical transduction rates reach 10-30% of neurons depending on serotype, dose, and injection route. The progressive nature of JNCL means treatment must be initiated before substantial neuronal loss; by the time of clinical diagnosis (often age 5-8 after vision loss), significant damage has occurred. For p.Val167Asp specifically, this missense variant may produce a protein that is synthesized but mistrafficked — if the mutant protein is retained in the ER rather than reaching lysosomes, there may be an ER stress component to pathology not fully addressed by wild-type CLN3 delivery to other cells. Immunosuppression regimens and durability of intrathecal AAV expression remain under investigation. No CLN3 gene therapy has entered human clinical trials as of early 2026.

Base Editing (ABE8e) via AAV9 delivery is a rationale-driven therapeutic strategy for Juvenile neuronal ceroid lipofuscinosis (CLN3 disease) targeting the CLN3 c.883G>A (p.Glu295Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct loss-of-function CLN3 variants (e.g., common 1.02-kb deletion) in CNS neurons to restore lysosomal/endolysosomal CLN3 function and slow or halt neurodegeneration in juvenile neuronal ceroid li. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: CLN3 NM_001042432.2(CLN3):c.883G>A (p.Glu295Lys) is classified as Pathogenic (ClinVar variation ID 3556). Molecular consequence: missense variant. Protein change: E295K, E195K, E217K, E271K, E241K. 2. Epidemiology: JNCL/CLN3 disease is the most common form of neuronal ceroid lipofuscinosis, with incidence estimates ranging from ~0.02 to 4.8 per 100,000 worldwide and overall Batten disease prevalence around 1 in 100,000 live births (PAPER-01, WEB-01). Onset typically occurs at 5-7 years with rapid progression a 3. Standard of care: There is no approved disease-modifying therapy specific for CLN3 disease; management is symptomatic and supportive, including seizure control, management of behavioral issues, visual impairment support, mobility aids, nutritional and respiratory support, and palliative care in a multidisciplinary se 4. Pipeline: For CLN3, an intrathecal AAV9-based gene therapy (AT-GTX-502) is in Phase I/II clinical trials (NCT03770572), with early data indicating good tolerability and possible slowing of motor decline compared with natural history (WEB-06, WEB-07, PAPER-04, PAPER-05, PAPER-06). Preclinical CNS AAV gene repl 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting CLN3 c.883G>A (p.Glu295Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.